FGFR2 and cholangiocarcinoma: In 2021, pemigatinib, the first targeted therapy for patients with unresectable cholangiocarcinoma previously treated with fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement has been approved based on the results of the phase II FIGHT-202 trial10.